No observed bidirectional effect between tenofovir diphosphate concentrations and gender‐affirming hormone concentrations among transgender persons switching from tenofovir disoproxil fumarate/emtricitabine to tenofovir alafenamide/emtricitabine for HIV pre‐exposure prophylaxis

Documenti analoghi

• Cluster headache‐like symptoms after initiation of tenofovir disoproxil fumarate and emtricitabine‐containing regimens for post‐ HIV exposure prophylaxis
  di: Alberto Foncillas, et al.
  Pubblicazione: (2024)
• Bictegravir/emtricitabine/tenofovir alafenamide in adults with HIV‐1 and end‐stage kidney disease on chronic haemodialysis
  di: Joseph J. Eron, et al.
  Pubblicazione: (2024)
• Risk of hepatocellular carcinoma after curative treatment when switching from tenofovir disoproxil fumarate or entecavir to tenofovir alafenamide: A real‐world multicenter cohort study
  di: Hyunjae Shin, et al.
  Pubblicazione: (2024)
• Evaluation of pharmacokinetic interactions between long‐acting cabotegravir or emtricitabine/tenofovir disoproxil fumarate and hormonal contraceptive agents: a tertiary analysis of South African participants in HPTN 084
  di: Mark A. Marzinke, et al.
  Pubblicazione: (2025)
• Metabolic effects of switching to Biktarvy (B/F/TAF) in patients with HIV‐1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF): The Metabic study
  di: C. Busca‐Arenzana, et al.
  Pubblicazione: (2024)